Phytochemical based on nanoparticles for neurodegenerative alzheimer disease management: Update review

Abstract Alzheimer’s disease (AD) is one of the most common chronic neurodegenerative diseases and dementia, with about 46 million cases worldwide and going to become tripled by 2050. It is characterized by formation and aggregation of amyloid- β plaques, tau tangles, and inflammatory mediators. The treatment protocol poses challenging obstacles particularly, effectiveness drug delivery to the brain. However, the available therapies with low potency and blood-brain barrier (BBB) are most challenges for developing novel treatments. New delivery systems that interact with biological systems at the molecular level, such as nanotechnology can overcome these problems and open new therapeutic avenues. Nanoparticles showed different applications in medicine due to its bioavailability, transport and low toxicity. This review explored the therapeutic potential of natural phytochemical nanomedicine that important in AD treatment through improving drug delivery system across BBB, increasing bioavailability and minimizing neurotoxicity. Graphical abstract